Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of physical restraint and poly I:C treatment on the growth of MOPC 104E myeloma and murine osteosarcoma and survival of animals bearing such tumors were investigated. Our studies show that in the Balb/c mice with MOPC 104E myeloma the effects of restraint stress were detrimental and lead to early death of the mice. When the restraint was combined with poly I:C, during the early course of the disease, restraint stress neutralized the beneficial effects of the poly I:C treatment. These studies show that under certain circumstances, restraint stress can negate the effects of therapy. On the other hand, restraint stress produced an opposite effect in C3H/He mice with murine osteosarcoma tumor treated in the same fashion. In mice with osteosarcoma, restraint stress delayed tumor growth and increased the median survival time. When restraint stress was combined with poly I:C treatment, the mean tumor size was smaller and median survival was substantially increased over the control group. Because poly I:C therapy delayed tumor growth and increased survival in both models, efforts to strengthen this response were tested by conditioning. Our studies show the response to poly I:C as measured by elevation of the NK activity could be conditioned with camphor smell. Conditioning of the host to raise immune activity to alter the outcome of disease is a new area yet to be explored and has important clinical significance. These studies, we believe, are important because they explore the connection between mind and body and resistance to disease.
 ...
PMID:Neural and environmental influences on neoplasia and conditioning of NK activity. 385 49

Hybrid cell lines have been derived from a fusion between mouse myeloma cells, NS1, and spleen cells from mice immunized with freshly resected osteosarcoma cells from an untreated patient. Of the 276 hybrids obtained, five secreted antibodies which bound to osteosarcoma tissues but not to autologous skin fibroblasts. The antibodies from three of these five hybrids, OST6, OST7, and OST15, reacted with all of five osteosarcoma tissues and with one chondrosarcoma tissue but not with other malignant or benign tumors. Tests of various normal tissues were negative, except for weak binding to a subpopulation of chondrocytes in articular cartilage. The reciprocal binding inhibition test showed that OST6, OST7, and OST15 antibodies were directed against different antigenic determinants.
 ...
PMID:Detection of human osteosarcoma-associated antigen(s) by monoclonal antibodies. 617 16

An organ-specific alkaline phosphatase inhibitor, L-homoarginine, at 44.5 mM concentration inhibited [3H]thymidine uptake by C3H/He mouse osteosarcoma (OS) cells, while L-arginine, L-phenylalanine, and glycine had little effect on the uptake. This inhibitory effect of L-homoarginine persisted even after the cells were washed free of the amino acid with fresh media. L-Homoarginine did not affect [3H]thymidine uptake by mouse myeloma MOPC 104E cells. In long-term culture, 22.3 mM L-homoarginine inhibited proliferation of OS cells. L-Arginine at the same concentration inhibited the proliferation to a lesser extent. On the other hand, L-phenylalanine and glycine did not affect in vitro proliferation of OS cells. When the same number of viable OS cells was inoculated s.c. after culturing the 24 hr with 44.5 mM L-homoarginine or L-arginine, the tumor growth in mice given injections of L-homoarginine (but not L-arginine)-treated cells was delayed markedly. Electron microscopic studies indicated that the inhibiting effect on OS cell proliferation was associated with a marked increase in lysosomal granules and a decrease in virus-like structures. Similarly, biochemical assay for acid phosphatase of cell homogenates demonstrated a 2-fold increase of activity in L-homoarginine-treated cells when compared to controls and L-arginine-treated cells. Thus, L-homoarginine inhibits proliferation and alkaline phosphatase activity of mouse OS cells and appears to increase acid phosphatase activity in synthesis of lysosomal granules.
 ...
PMID:Inhibitory effect of L-homoarginine on murine osteosarcoma cell proliferation. 617 11

An organ-specific alkaline phosphatase (AIP) inhibitor, L-homoarginine at 44.5 mM concentration inhibited 3H-thymidine uptake by mouse C3H/He osteosarcoma (OS) cells, while L-arginine, L-phenylalanine and L-glycine had little effect on the uptake. This inhibitory effect by L-homoarginine persisted even after the cells were washed free of the amino acid with fresh media. L-homoarginine did not affect 3H-thymidine uptake by mouse myeloma MOPC 104E cells. In the long-term culture, 22.3 mM L-homoarginine inhibited proliferation of OS cells. L-Arginine at the same concentration inhibited the proliferation to a lesser extent. On the other hand, L-phenylalanine and L-glycine did not affect in vitro proliferation of OS cells. When similar numbers of viable OS cells were inoculated s. c. after culturing with 44.5 mM L-homoarginine or L-arginine for 24 hr, the tumor growth in mice injected with L-homoarginine (but not L-arginine) treated cells was delayed markedly. Electron microscopic studies indicated that the inhibitory effect on OS cell proliferation was associated with a marked increase in lysosomal granules and a decrease in virus-like structures. Similarly, a biochemical assay of acid phosphatase (AcP) of the cell homogenates demonstrated two-fold increase of the activity in L-homoarginine treated cells when compared to the controls and L-arginine treated cells. Thus, L-homoarginine inhibits proliferation and AIP activity of mouse OS cells and appears to promote cell differentiation as evidenced by the increased synthesis of cytoplasmic granules and acid phosphatase activity.
 ...
PMID:[Inhibitory effect of L-homoarginine on murine osteosarcoma cell proliferation]. 619 5

Hybrid cell lines have been derived from a fusion between mouse myeloma cell line, NS1/Ag 4-1, and spleen cells from BALB/c mice immunized with freshly resected osteosarcoma cells from an untreated patient. Of the 276 hybrids obtained, five secreted antibodies which bound to osteosarcoma tissues but not to autologous skin fibroblasts. Antibodies secreted by individual hybrids were tested for their reaction with a panel of human normal and tumor tissues in an immunofluorescence assay, and they displayed different specificities. Two of these antibodies, OST2 and OST4, bound to osteosarcoma tissues and to some other tumors and normal tissues. The antibodies from three of these five hybrids, OST6, OST7, and OST15, reacted with all of seven osteosarcoma tissues and one chondrosarcoma tissue but not with other malignant or benign tumors. Tests of various normal tissues were negative, except for weak binding to a subpopulation of chondrocytes in calcified areas of cartilage near the subchondral bone. Interestingly, none of the antibodies showed reactivity with three osteosarcoma cell lines, Te 85, Te 418, and MG 63. The experiments established the usefulness of the hybridoma technique in preparing monospecific antibodies against human osteosarcoma associated antigens. In particular, this study demonstrates that the use of freshly resected tumor tissues in preparing monoclonal antibodies would provide a necessary tool for the study of tumor associated antigens.
 ...
PMID:[Detection of human osteosarcoma-associated antigens by monoclonal antibodies]. 657 22

Fifty patients with bone primary tumors (multiple myeloma, osteogenic sarcoma, Ewing's sarcoma, giant cell tumor, and others) were studied gammagraphically after injecting 555 MBq of 99mTc-MDP. Eighty per cent of the cases were found in long bones, specially femur and tibia. These two bones were the preferent localization of osteosarcomas. Ewing's neoplasms were mostly diaphysial and osteoclastomas epiphysial.
 ...
PMID:[Bone and vascular gammagraphy in the study of primary bone neoplasms. Diagnostic value and monitoring of clinical course. Review of 50 cases]. 659 9

Monoclonal antibody against an osteogenic-sarcoma cell line (791T) was prepared by production and cloning of a somatic-cell hybrid between the mouse myeloma P3-NS1 and spleen cells from 791T-immunized mice. Three clones of hybridoma producing antibody against 791T, as detected by 125I-labelled Protein A binding, were tested against a range of normal and tumour cell targets to determine the pattern of expression of the antigen detected. The 3 clones had identical activity. They reacted strongly against 791T cells and another osteogenic sarcoma, 788T, and more weakly against a further 2 from a total panel of 10 osteogenic-sarcoma lines. The antibody was negative for fibroblasts from the donor of 791T, and for other fibroblasts, human red blood cells, human peripheral mononuclear cells and sheep red blood cells. When tested against a panel of unrelated tumours, they reacted against individual cell lines derived from carcinomas of colon, lung, bladder and cervix. These cross-reactions were not observed with other colon or lung carcinomas, and it is suggested that the antibody was reacting with a tumour-associated antigen expressed randomly on different tumour types, rather than specifically on osteogenic sarcomas.
 ...
PMID:Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line. 694 6

Any pathological damage occurring in a bone will produce either an osteolytic or osteosclerotic lesion which can be seen in the macroscopic specimen as well as in the roentgenogram. Various bone lesions may lead to local destructions of the bone. An osteoma or osteoplastic osteosarcoma produces an osteosclerotic lesion showing a dense mass in the roentgenogram; a chondroblastoma or an osteoclastoma, on the other had, induces an osteolytic focal lesion. This paper presents examples of different osteolytic lesions of the humerus. An osteolytic lesion seen in the roentgenogram may be either produced by an underlying non-ossifying fibroma of the bone, by fibrous dysplasia, osteomyelitis or Ewing's sarcoma. Differential diagnostic considerations based on the radiological picture include eosinophilic bone granuloma, juvenile or aneurysmal bone cyst, multiple myeloma or bone metastases. Serious differential diagnostic problems may be involved in case of osteolytic lesions occurring in the humerus. Cases of this type involving complications have been reported and include the presence of an teleangiectatic osteosarcoma as well as that of a hemangiosarcoma of the bone.
 ...
PMID:[Intraosseous osteolytic lesions. Diagnostic, differential diagnosis and therapy (author's transl)]. 694 21

Monoclonal antibodies directed against one spontaneously arising rat mammary carcinoma and a human osteogenic sarcoma have been prepared following the fusion of spleen cells from appropriately immunised donors with mouse myeloma cells. The characteristics of these antibodies have been analysed and methods for their purification have been developed using immunoadsorption chromatography or by utilising their affinity for Sepharose-linked Protein A. The use of these antibodies for the identification, characterisation and isolation of their target tumour antigenic structures is described.
 ...
PMID:Characteristics of two anti-tumour monoclonal antibody preparations. 694 20

One hundred ten patients with primary chest wall neoplasms were analyzed for long-term results. The diagnosis of 59 malignant and 51 benign tumors was confirmed by the Armed Forces Institute of Pathology. No deaths were associated with primary definitive therapy. Among the five most frequently encountered malignant tumor types, five-year survivals were obtained in 9 of 17 (53%) patients with fibrosarcoma, 8 of 9 (89%) patients with chondrosarcoma, 2 of 8 (25%) patients with solitary chest wall plasmacytoma (multiple myeloma), 1 of 6 (17%) patients with Ewing's sarcoma, and 2 of 4 (50%) of patients with osteogenic sarcoma. Although the five-year survival appears to indicate therapeutic success in patients with Ewing's sarcoma and osteogenic sarcoma, patients with chondrosarcoma or fibrosarcoma may have a more protracted course, and those with solitary plasmacytoma usually develop multiple myeloma. The findings suggest that radical surgical excision is the treatment of choice for chondrosarcoma; radical surgical excision combined with chemotherapy, for fibrosarcoma and osteogenic sarcoma; surgical excision combined with radiation and chemotherapy, for Ewing's sarcoma; and systemic surveillance and therapy, for pathologically confirmed solitary plasmacytoma.
 ...
PMID:Initial and long-term results in the management of primary chest wall neoplasms. 695 75


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>